{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062257","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.378447+00:00","generated_at":"2026-06-01T21:17:48.307937+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Voyager Therapeutics doses first participants in Phase 1a trial of anti-tau antibody VY-TAU01 for Alzheimer's","bullets":["First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.","Trial is randomized, double-blind, placebo-controlled, evaluating safety and PK in healthy adult volunteers.","Study conducted at a single U.S. site; expected to enroll approximately 48 patients across multiple cohorts.","VY-TAU01 designed to inhibit spread of pathological tau in Alzheimer's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062257","json":"https://secwatch.observer/filing/0001104659-24-062257.json","markdown":"https://secwatch.observer/filing/0001104659-24-062257.md","text":"https://secwatch.observer/filing/0001104659-24-062257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924062257/0001104659-24-062257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924062257/tm2414591d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:17:48.307937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}